Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Clinical Outcomes of Ultra-Low PSA Responses in Patients With mHSPC Receiving Darolutamide Plus ADT

Summary by urologytime.com
Research reveals that lower PSA levels in metastatic hormone-sensitive prostate cancer significantly delay disease progression and improve patient outcomes.

3 Articles

ProtothemaProtothema
Right

Therapeutic Advances in Prostate Cancer Even for Patients with Metastatic Disease

More aggressive treatment of the disease and the use of new therapies can increase patient survival.

Read Full Article
urologytime.comurologytime.com
Reposted by
urologytimes.comurologytimes.com

Clinical Outcomes of Ultra-Low PSA Responses in Patients With mHSPC Receiving Darolutamide Plus ADT

Research reveals that lower PSA levels in metastatic hormone-sensitive prostate cancer significantly delay disease progression and improve patient outcomes.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources lean Right
100% Right

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

urologytime.com broke the news in on Monday, May 19, 2025.
Sources are mostly out of (0)

Similar News Topics

Research icon

Research

News
For You
SearchBlindspotLocal